Bank of New York Mellon Corp Reduces Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Bank of New York Mellon Corp reduced its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGOFree Report) by 41.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 223,906 shares of the medical instruments supplier’s stock after selling 161,358 shares during the period. Bank of New York Mellon Corp owned about 0.56% of AngioDynamics worth $1,637,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Gladius Capital Management LP bought a new position in shares of AngioDynamics in the third quarter worth approximately $31,000. Nuveen Asset Management LLC grew its holdings in shares of AngioDynamics by 18.3% in the second quarter. Nuveen Asset Management LLC now owns 507,253 shares of the medical instruments supplier’s stock worth $5,291,000 after purchasing an additional 78,438 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of AngioDynamics by 11.5% in the second quarter. Alliancebernstein L.P. now owns 42,580 shares of the medical instruments supplier’s stock worth $444,000 after purchasing an additional 4,380 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of AngioDynamics by 67.4% in the second quarter. Wells Fargo & Company MN now owns 16,585 shares of the medical instruments supplier’s stock worth $173,000 after purchasing an additional 6,676 shares during the last quarter. Finally, Public Employees Retirement System of Ohio grew its holdings in shares of AngioDynamics by 271.7% in the second quarter. Public Employees Retirement System of Ohio now owns 33,462 shares of the medical instruments supplier’s stock worth $349,000 after purchasing an additional 24,459 shares during the last quarter. 90.52% of the stock is currently owned by institutional investors.

AngioDynamics Stock Up 1.4 %

Shares of ANGO stock opened at $5.94 on Wednesday. The stock has a fifty day moving average of $6.79 and a 200 day moving average of $7.21. AngioDynamics, Inc. has a 52 week low of $5.67 and a 52 week high of $13.30. The firm has a market capitalization of $236.71 million, a price-to-earnings ratio of -16.97 and a beta of 0.69.

AngioDynamics (NASDAQ:ANGOGet Free Report) last announced its quarterly earnings results on Friday, January 5th. The medical instruments supplier reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04. The company had revenue of $79.07 million during the quarter, compared to analyst estimates of $81.65 million. AngioDynamics had a negative return on equity of 1.78% and a negative net margin of 4.28%. Equities research analysts anticipate that AngioDynamics, Inc. will post -0.38 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on ANGO. Raymond James cut their target price on shares of AngioDynamics from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday, January 9th. HC Wainwright dropped their price target on AngioDynamics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, January 8th.

Read Our Latest Report on AngioDynamics

About AngioDynamics

(Free Report)

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.

See Also

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.